: Despite the exemplary efficacy of voltage-gated sodium channel blockers as a first-line treatment of trigeminal neuralgia, the pharmacological management of this excruciating facial pain condition remains a major issue, as these first-line drugs produce intolerable side effects in a significant portion of patients. In addition, in patients with concomitant continuous pain, the efficacy of these drugs may drop, thus suggesting the opportunity to test the efficacy of different drug categories. The aim of this review is to provide current, evidence-based, knowledge about the use of gabapentin and other α2δ ligands in patients with trigeminal neuralgia. We searched for relevant papers within PubMed, EMBASE, the Cochrane Database of Systematic Reviews and the Clinical Trials database (ClinicalTrials.gov), considering publications up to April 2023. Two authors independently selected studies for inclusion and data extraction. The efficacy of α2δ ligands, gabapentin and pregabalin, has been assessed in seven controlled or open-label studies. Despite the low quality of evidence, the favorable tolerability profile and the possible action on concomitant continuous pain make this drug category of interest for future trials in trigeminal neuralgia.

Considerations ehen using gabapentinoids to treat trigeminal neuralgia: a review / DE STEFANO, Gianfranco; DI PIETRO, Giuseppe; Truini, Andrea; Cruccu, Giorgio; DI STEFANO, Giulia. - In: NEUROPSYCHIATRIC DISEASE AND TREATMENT. - ISSN 1176-6328. - 19:(2023), pp. 2007-2012. [10.2147/NDT.S407543]

Considerations ehen using gabapentinoids to treat trigeminal neuralgia: a review

Gianfranco De Stefano
Co-primo
;
Giuseppe Di Pietro
Co-primo
;
Andrea Truini;Giorgio Cruccu;Giulia Di Stefano
Ultimo
2023

Abstract

: Despite the exemplary efficacy of voltage-gated sodium channel blockers as a first-line treatment of trigeminal neuralgia, the pharmacological management of this excruciating facial pain condition remains a major issue, as these first-line drugs produce intolerable side effects in a significant portion of patients. In addition, in patients with concomitant continuous pain, the efficacy of these drugs may drop, thus suggesting the opportunity to test the efficacy of different drug categories. The aim of this review is to provide current, evidence-based, knowledge about the use of gabapentin and other α2δ ligands in patients with trigeminal neuralgia. We searched for relevant papers within PubMed, EMBASE, the Cochrane Database of Systematic Reviews and the Clinical Trials database (ClinicalTrials.gov), considering publications up to April 2023. Two authors independently selected studies for inclusion and data extraction. The efficacy of α2δ ligands, gabapentin and pregabalin, has been assessed in seven controlled or open-label studies. Despite the low quality of evidence, the favorable tolerability profile and the possible action on concomitant continuous pain make this drug category of interest for future trials in trigeminal neuralgia.
2023
gabapentin; pregabalin; trigeminal neuralgia
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Considerations ehen using gabapentinoids to treat trigeminal neuralgia: a review / DE STEFANO, Gianfranco; DI PIETRO, Giuseppe; Truini, Andrea; Cruccu, Giorgio; DI STEFANO, Giulia. - In: NEUROPSYCHIATRIC DISEASE AND TREATMENT. - ISSN 1176-6328. - 19:(2023), pp. 2007-2012. [10.2147/NDT.S407543]
File allegati a questo prodotto
File Dimensione Formato  
De Stefano_Considerations_2023.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.46 MB
Formato Adobe PDF
1.46 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1689600
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact